What dose of BPC-157 is established in humans?

None. There is no dose established in controlled trials, no approved dose, and no prescribing-label dose for BPC-157. The only published human work was a small open-label oral pilot that was not designed to set an effective or safe dose. Any figure quoted is an extrapolation from animal studies, not an established protocol.

Where do the microgram figures online come from?

They are back-calculated from preclinical rodent studies that dosed BPC-157 in the microgram-to-nanogram-per-kilogram range, then scaled to a human body weight by allometric conversion. That conversion is a crude estimate, not a procedure validated for this peptide, and it says nothing about human safety or efficacy.

Why does PepVise not give a specific BPC-157 dose?

Because no human dose is established and because we do not recommend administering an unapproved research peptide. A number from a website is no substitute for assessment by a licensed physician working within FDA-compliant pathways. We describe what the literature reports and leave any use decision to medicine.

Does research-chemical purity make the dose unusable?

Yes. Sold as a research chemical, BPC-157 carries no pharmaceutical quality control, and the real active content of a vial can differ from the stated value. A dose calculated in micrograms is worthless if the actual concentration in the solution is unknown.

Does the route of administration matter for the dose?

It is decisive. The oral bioavailability of a peptide differs fundamentally from that of an injection, and the human data come from an oral formulation while much of the animal data used local or subcutaneous injection. Transferring a number from one route to another is pharmacologically indefensible.

Explainer· Compounds

BPC-157 dosage, what the literature shows

By The PepVise Editorial Team · Reviewed July 14, 2026 · 11 min read

Why there is no established human dose for BPC-157, where the microgram figures circulating online actually come from, and why the unknown concentration and purity of research chemicals make any dose meaningless. PepVise prescribes nothing.

Mechanism explainers on PepVise aim for textbook-level clarity without the textbook's refusal to commit to a reading.

Frequently asked

What readers ask us next.

What dose of BPC-157 is established in humans?: None. There is no dose established in controlled trials, no approved dose, and no prescribing-label dose for BPC-157. The only published human work was a small open-label oral pilot that was not designed to set an effective or safe dose. Any figure quoted is an extrapolation from animal studies, not an established protocol.
Where do the microgram figures online come from?: They are back-calculated from preclinical rodent studies that dosed BPC-157 in the microgram-to-nanogram-per-kilogram range, then scaled to a human body weight by allometric conversion. That conversion is a crude estimate, not a procedure validated for this peptide, and it says nothing about human safety or efficacy.
Why does PepVise not give a specific BPC-157 dose?: Because no human dose is established and because we do not recommend administering an unapproved research peptide. A number from a website is no substitute for assessment by a licensed physician working within FDA-compliant pathways. We describe what the literature reports and leave any use decision to medicine.
Does research-chemical purity make the dose unusable?: Yes. Sold as a research chemical, BPC-157 carries no pharmaceutical quality control, and the real active content of a vial can differ from the stated value. A dose calculated in micrograms is worthless if the actual concentration in the solution is unknown.
Does the route of administration matter for the dose?: It is decisive. The oral bioavailability of a peptide differs fundamentally from that of an injection, and the human data come from an oral formulation while much of the animal data used local or subcutaneous injection. Transferring a number from one route to another is pharmacologically indefensible.

The sources

References cited on this page.

PubMed, ClinicalTrials.gov, and FDA documents only. Secondary sources appear when needed to characterize public discourse, never as a source for a clinical claim.

The masthead

About The Pepvise Editorial Team

The Pepvise Editorial Team is a small group of researchers and science writers reading the peer-reviewed peptide literature and translating it into calm, cited analysis. We do not sell peptides, recommend peptides, or tell readers what to administer. We describe what has been measured, by whom, at what scale, with what effect size.

Compound reviews are signed off by Dr. Priya Narang, MD, MPH (endocrinologist) and Dr. Marcus Haley, PharmD, BCPS (board-certified clinical pharmacist). Both hold verifiable state-board licenses and have signed editorial-independence letters with us. See the full editorial board →

Adjacent in the literature.

Compounds · Compound profile

BPC-157, What the Evidence Shows

Evidence Ledger for BPC-157: 50+ preclinical studies, 1 human pilot (Chang 2014, n=12), 1 active Phase trial, FDA removed from 503A list in 2023.

16 min read

Compounds · Compound profile

TB-500, The Field Guide

TB-500 vs Thymosin Beta-4 (same compound), mechanism, the preclinical tendon and recovery literature, and where the human data is thin.

14 min read

Compounds · Compound profile

GHK-Cu, Evidence and Hype

Copper peptide signaling, the topical RCT evidence for hair and skin, and the gap between topical and injectable claims.

13 min read

Get the 2026 Peptide Evidence Ledger.

A 12-page PDF summary of where 10 major compounds sit, Preclinical / Human pilot / Phase trial / FDA status. Updated quarterly. Free.

By subscribing, you agree to our Privacy Policy. One calm, cited email a week. Unsubscribe anytime.